Advertisement
Advertisement
U.S. Markets close in 5 hrs 36 mins
Advertisement
Advertisement
Advertisement
Advertisement

Olema Pharmaceuticals, Inc. (OLMA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9600+0.1000 (+3.50%)
As of 10:23AM EDT. Market open.
Advertisement

Olema Pharmaceuticals, Inc.

512 2nd Street
4th Floor
San Francisco, CA 94107
United States
650 243 5555
https://www.olema.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Dr. Sean P. Bohen M.D., Ph.D.Pres, CEO & Director999.3kN/A1967
Mr. Shane William Charles Kovacs M.B.A.Chief Operating & Financial Officer875.55kN/A1974
Dr. Cyrus L. Harmon Ph.D.CTO & DirectorN/AN/A1971
Mr. Kinney HornChief Bus. Officer588.3kN/A1974
Dr. Peter J. Kushner Ph.D.Co-Founder & Sr. Research FellowN/AN/A1939
Ms. Eva StroynowskiVP of Communications & Investor RelationsN/AN/AN/A
Mr. John B. Moriarty Jr.Exec. VP, Chief Legal Officer & Corp. Sec.N/AN/A1968
Ms. Julie DexterVP & Head of PeopleN/AN/AN/A
Dr. David C. MylesChief Devel. OfficerN/AN/A1963
Ms. Demiana FaltaosVP & Head of Clinical PharmacologyN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Corporate Governance

Olema Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement